Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA

Future Oncol. 2024;20(16):1079-1097. doi: 10.2217/fon-2023-0363. Epub 2024 Feb 21.

Abstract

Aim: Real-world treatment patterns in tenosynovial giant cell tumor (TGCT) patients remain unknown. Pexidartinib is the only US FDA-approved treatment for TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery. Objective: To characterize drug utilization and treatment patterns in TGCT patients. Methods: In a retrospective observational study using IQVIA's linked prescription and medical claims databases (2018-2021), TGCT patients were stratified by their earliest systemic therapy claim (pexidartinib [N = 82] or non-FDA-approved systemic therapy [N = 263]). Results: TGCT patients treated with pexidartinib versus non-FDA-approved systemic therapies were predominantly female (61 vs 50.6%) and their median age was 47 and 54 years, respectively. Pexidartinib-treated patients had the highest 12-month probability of remaining on treatment (54%); 34.1% of pexidartinib users had dose reduction after their first claim. Conclusion: This study provides new insights into the unmet need, utilization and treatment patterns of systemic therapies for the treatment of TGCT patients.

Keywords: PVNS; TGCT; dose reduction; drug utilization; epidemiology; pexidartinib; pigmented villonodular synovitis; systemic therapies; tenosynovial giant cell tumor; treatment duration; treatment patterns; unmet need.

Plain language summary

Treatment patterns in patients with tenosynovial giant cell tumors in the USAThis database study is the first investigation of how drugs are used to treat patients with tenosynovial giant cell tumor (TGCT) in the real world. We researched adult TGCT patients from IQVIA's prescription and medical claims databases who started treatment with pexidartinib (N = 82) or other non-US FDA-approved systemic therapies (N = 263). The patients included in this analysis were mostly women (61.0 and 50.6%) and their median age was 47 and 54 years for pexidartinib and other non-FDA-approved systemic therapies, respectively. The patients treated with pexidartinib were most likely to remain on treatment (54.0%) at the end of the first year. Most patients (79.3%) started pexidartinib treatment at a total daily dose of 800 mg/day, as per the product label. Only 34.1% of patients had reduced medication dose during follow-up. Of note, this study found that TGCT patients were treated with other systemic therapies which remain unproven to be safe and effective in medical studies of TGCT. Given the unmet need, and with pexidartinib being the only approved systemic treatment in USA, there is an opportunity for the larger population of adult TGCT patients to benefit from its use. Further research is needed to identify barriers for access to pexidartinib and treatment of TGCT patients.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Aged
  • Aminopyridines / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Drug Utilization / statistics & numerical data
  • Female
  • Giant Cell Tumor of Tendon Sheath* / drug therapy
  • Giant Cell Tumor of Tendon Sheath* / pathology
  • Humans
  • Male
  • Middle Aged
  • Pyrroles
  • Retrospective Studies
  • United States

Substances

  • pexidartinib
  • Aminopyridines
  • Antineoplastic Agents
  • Pyrroles